Human γδ T lymphocytes for immunotherapeutic strategies against cancer

F1000 Medicine Reports

Volumn 2, Issue 1, 2010, Pages

  Kabelitz, Dieter ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOBISPHOSPHONATE; GEMCITABINE; GERANYLTRANSFERASE; INTERLEUKIN 2 DERIVATIVE; ISOPENTENYL DIPHOSPHATE; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PHOSPHONIC ACID DERIVATIVE; PYROPHOSPHATE; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CELL PROLIFERATION; CELL TRANSFORMATION; CYTOTOXICITY; HUMAN; LOW DRUG DOSE; NEOPLASM; OSTEOPOROSIS; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; TREATMENT PLANNING; TUMOR CELL;

EID: 77955078183     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M2-45     Document Type: Review

References (26)

1. Hayday A: γδ T cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000, 18:975-1026.
2. Hayes SM, Love PE: TCR signal strength influences αβ/ γδ lineage fate. Immunity 2005, 22:583-93.
3. Brandes M, Willimann K, Moser B: Professional antigen-presentation function by human γδ T cells. Science 2005, 309:264-8.
4. Morita CT, Jin C, Sarikonda G, Wang H: Nonpeptide antigens, presentation mechanisms, and immunologic memory of human Vg2Vd2 T cells: discriminating friend from foe through the recognition of prenylpyrophosphate antigens. Immunol Rev 2007, 215:59-76. (Pubitemid 46212230)
5. Kabelitz D: Small molecules for the activation of human γδ T cell responses against infection. Recent Pat Anti-Infect Drug Discov 2008, 3:1-9.
6. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M: Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-92.
7. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, Kabelitz D, Wesch D: Lysis of a broad range of epithelial tumour cells by human γδ T cells: Involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol 2007, 66:320-8.
8. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, de Libero G: Human T cell receptor γδ T cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003, 197:163-8. (Pubitemid 36152311)
9. Thompson K, Roelofs AJ, Jauhiainen M, Mönkkönen H, Mönkkönen J, Rogers MJ: Activation of γδ T cells by bisphosphonates. Adv Exp Med Biol 2010, 658:11-20.
10. Kabelitz D, Wesch D, He W: Perspectives of γδ T cells in tumor immunology. Cancer Res 2007, 67:5-8.
11. + T cell isolation kit'. J Immunol Methods 2009, 347:12-8.
12. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, Goto S, Yokokawa K, Suzuki K: Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009, 37:956-68.
13. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H: Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007, 56:469-76.
14. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Négrier S: Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008, 57:1599-609.
15. Li J, Herold MJ, Kimmerl B, Müller I, Rincon-Orozco B, Kunzmann V, Herrmann T: Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vγ9Vδ2 T cells. J Immunol 2009, 182:8118-24.
16. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M, Hayday A: Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007, 67:7450-7.
17. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP: γδ T cells for immune therapy of patients with lymphoid malignancy. Blood 2003, 102:200-6.
18. Laggner U, Lopez JS, Perera G, Warbey VS, Sita-Lumsden A, O'Doherty MJ, Hayday A, Harries M, Nestle FO: Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localized radiotherapy. Clin Immunol 2009, 131:367-73.
19. Clezardin P, Ebertino FH, Fournier PG: Bisphosphonates and cancer-induced bone disease: beyond their anti-resorptive activity. Cancer Res 2005, 65:4971-4. (Pubitemid 40827299)
20. Simoni D, Gebbia N, Invidiata FP, Eleopra M, Marchetti P, Rondanin R, Baruchello R, Provera S, Marchioro C, Tolomeo M, Marinelli L, Limongelli V, Novellino E, Kwaasi A, Dunford J, Buccheri S, Caccamo N, Dieli F: Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo anti-tumor activity through a gd-T lymphocytes-mediated activation mechanism. J Med Chem 2008, 51:6800-7.
21. Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sao K, Hosoi A, Nakajima J, Yoshida Y, Shiraishi K, Nakagawa K, Kakimi K: Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008, 10:842-56.
22. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, Fai-So H, Moriyasu F, Nieda M, Nicol AJ: Vg9Vd2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - rituximab and trastuzumab. Int J Cancer 2008, 122:2526-34.
23. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, Cendron D, Gross E, Lepage JF, Quillet-Mary A, Ysebaert L, Laurent G, Sicard H, Fournié JJ: Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 2009, 113:4875-84.
24. Boyman O, Létourneau S, Krieg C, Sprent J: Homeostatic proliferation and survival of naïve and memory T cells. Eur J Immunol 2009, 39:2088-94.
25. Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet S: IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human Vγ9Vδ2 T cells for adoptive immunotherapy. J Immunol 2009, 182:3423-31.
26. Mattarollo SR, Kenna T, Nieda M, Nicol AJ: Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunol Immunother 2007, 56:1285-97.